| Location | San Francisco - 1800 Owens, CA |
What You'll Do
The Senior Director, GTM Strategy & Portfolio Planning will own the long-term go-to-market strategy for encaleret (BridgeBio's oral CaSR negative allosteric modulator for Autosomal Dominant Hypocalcemia Type 1) and shape how BridgeBio prioritizes and sequences investment across its broader endocrine portfolio. This role sits at the center of pre-launch strategy, indication sequencing, and portfolio-level resource planning, translating deep market and competitive insight into a durable multi-year commercial roadmap. The ideal candidate is a systems-level strategic thinker who has led at least one rare disease launch and can move fluidly between long-range portfolio strategy and the field-level realities that make a launch succeed. You will report to the SVP, Sales & Marketing - Endocrinology, and be based in the San Francisco Bay Area with regular in-office collaboration.
Responsibilities
Where You'll Work
This is a hybrid, San Francisco Bay Area-based role, with in-office collaboration expected Tuesday through Thursday weekly across our San Francisco and Palo Alto offices, and ~25% travel for key congresses, advisory boards, and field engagement.
Who You Are